Intercept Pharma (ICPT) Announces Restructuring

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. AA
10. TECHM:IN

Go back to Intercept Pharma (ICPT) Announces Restructuring

Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses

June 23, 2023 6:30 AM EDT

Measures reinforce Companys ability to drive growth in PBC business and continue developing innovative new medicines Company to discontinue all NASH-related investment and reduce workforce by approximately one third Company anticipates achieving profitability in 2024R&D investment prioritized on fixed-dose combination of OCA and bezafibrate with potential to establish best-in-class clinical benefits in the treatment of PBCCompany lowers 2023 non-GAAP adjusted operating expense guidance to $350$370 million, inclusive of restructuring costs; reiterates 2023 Ocaliva net sales guidance of $310$340... More